Trial Phase
Trial Status
Paid Participation
Trial Details
Key Eligibility Criteria
1400 Participants Needed
Trial Details
Key Eligibility Criteria
2500 Participants Needed
Trial Details
Key Eligibility Criteria
800 Participants Needed
Trial Details
Key Eligibility Criteria
188 Participants Needed
Trial Details
Key Eligibility Criteria
767 Participants Needed
Trial Details
Key Eligibility Criteria
927 Participants Needed
Trial Details
Key Eligibility Criteria
150 Participants Needed
Trial Details
Key Eligibility Criteria
40 Participants Needed
Trial Details
Key Eligibility Criteria
200 Participants Needed
Know someone looking for new options?
Spread the word
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
"I've been battling multiple sclerosis for 28 years. I've tried three medications. I keep my dosing stable, but I'm just tired of managing. I want to take control of my situation."
"I've tried 2 MS drugs but I am getting worse. I am having trouble walking long distances or for more than 30 minutes. I need to find a new medication. My doctor and I discussed some of the options in trials and I'm ready to dive in to learn more."
"I have been losing mobility in the past 3 years very rapidly. I have tried physical therapy, but it didn't really show results. I'll admit that I am not very self-motivated, so I can use some structure. I use to be extremely active and now I am like a wet rag. So I am hoping that participating in a research trial will be of help to me."
"I've been taking Kesimpta for a couple years now and seem to be having more flare ups. I'm only 43. I have 5 kids and feel like I'm missing my life. Sleeping my life away. I'm ready to try ANYTHING for a chance at living life again."
"I am 42 yrs old with 2 little kids, work as a nurse, tried several drugs, most made me feel awful. I want my quality of life. I don’t want to have to take something daily/monthly. I don’t like the side effects of many drugs. I'm excited to be considered as a candidate for one of these trials."
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple Sclerosis trials in Alaska 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Alaska for Multiple Sclerosis is 12 months.
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Alaska several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
Most recently, we added BMS-986368 for Multiple Sclerosis, Exercise for Multiple Sclerosis and Tolebrutinib for Multiple Sclerosis to the Power online platform.
Yes. In relapsing-remitting MS the immune attack can quiet down for weeks, months, or even years, letting symptoms ease or disappear; neurologists try to extend these quiet spells—called remission or “no evidence of disease activity” (NEDA)—with early use of disease-modifying drugs, healthy habits, and regular MRI checks. Remission isn’t a cure because slow nerve damage can still smolder, and it is uncommon in secondary- or primary-progressive MS, so sticking with treatment and follow-up appointments remains vital even when you feel well.
Death certificates show that the commonest “underlying” cause of death in people with MS is the disease itself (ICD-10 G35), accounting for roughly half of all deaths; this label usually stands for advanced disability complicated by infections and breathing problems. Cardiovascular disease and cancer trail well behind (each about one-tenth to one-fifth of deaths), so focusing on preventing aspiration, treating infections quickly, staying mobile, and managing heart-health risks offers the biggest leverage for living longer with MS.
Think of “don’ts” in three buckets: 1) anything that drives inflammation (smoking, heavy drinking, high-salt or highly processed, high-saturated-fat foods); 2) anything that lets the body decondition or overheat (long periods of inactivity, extreme heat without cooling strategies); and 3) anything that interferes with treatment safety (skipping or delaying prescribed medicines, starting high-dose supplements or live vaccines, or stopping disease-modifying therapy without your neurologist’s okay). Steering clear of these pitfalls, while staying active, eating mostly whole foods, and working closely with your MS team, gives the best chance of slowing attacks and disability.
Doctors now have a spinal-fluid test called the “kappa free light-chain (KFLC) index,” which measures tiny antibody pieces instead of looking for oligoclonal bands. In several large studies it identified multiple sclerosis with about 90–95 % sensitivity and 85–90 % specificity, is run on an automated machine (so it’s faster, cheaper, and less subjective), and many centers are beginning to add it to the standard work-up, although it still requires a lumbar puncture and currently complements rather than fully replaces oligoclonal-band testing.
Multiple sclerosis is recognized by disability laws in the U.S., U.K., Canada and many other countries, but you are considered “disabled” only if your specific symptoms—such as fatigue, vision loss, or mobility problems—limit everyday tasks or steady work despite treatment. Because MS progression varies widely (some stay mild for decades while roughly one-third need a cane within 15 years), keep detailed medical records and talk with your neurologist, employer, or a benefits adviser early to document limitations, request job accommodations, or file for disability support if needed.
There isn’t a “normal” or required lesion count for multiple sclerosis: some people have none on the first MRI, others show a handful, and studies put the typical range at roughly 5–15 lesions. What matters more to doctors is where the spots are and whether new ones appear over time—four or more lesions, especially in key areas like around the ventricles, can raise concern for future disability, but prognosis depends on the pattern and evolution rather than any single number.
So far no treatment has reliably “turned MS off” for everyone, but limited reversal of disability can occur. Many patients regain some or all lost function after a relapse, and small clinical trials of autologous stem-cell transplantation show that about 50-70 % of carefully selected, highly active cases improve their disability scores for several years, though the procedure carries notable risks and is not yet routine care. Current disease-modifying drugs aim to prevent new damage, and research into remyelination medicines is underway, but a guaranteed, widely available way to reverse MS does not yet exist.
Yes, the head-count of people living with multiple sclerosis is climbing worldwide—up roughly one-third since 1990—largely because people are being diagnosed earlier and living longer with the disease. New cases per year (incidence) have risen only modestly and unevenly, suggesting that improved detection and better treatments, rather than an explosive growth in risk, account for most of the increase, though lifestyle factors such as low vitamin D, obesity, smoking and EBV infection may also play a smaller role.
MS can cluster in families, but it is not passed down in a simple all-or-nothing way: the lifetime chance is about 1 in 300 for anyone, rises to roughly 1 in 30 (≈2–3 %) if you have a parent, child, or sibling with MS, and even identical twins match only about 1 in 4 times—proof that genes are only part of the story. Because most relatives never develop the disease, routine genetic testing isn’t recommended; instead, general health steps that may lower risk (adequate vitamin D, avoiding smoking, healthy weight) are sensible for everyone.
Treatment for progressive MS has two parts. First, disease-modifying drugs such as ocrelizumab (for primary-progressive) and siponimod or, in some cases, cladribine/rituximab (for active secondary-progressive) can slow further disability when started early under an MS specialist’s care. Second, an ongoing personalised plan—physiotherapy and exercise, medicines for spasticity, pain, bladder or fatigue, plus good sleep, diet, vaccination and prompt treatment of infections—helps control day-to-day symptoms and prevents complications, with regular reviews to adjust both pieces as the condition evolves.
